Advanced Treatment for Wet AMD, Diabetic Retinopathy, and DME at South Carolina Retina Institute

Advanced Treatment for Wet AMD, Diabetic Retinopathy, and DME at South Carolina Retina Institute

Age-related macular degeneration (AMD) poses a significant threat to vision, impacting the lives of many individuals. At South Carolina Retina Institute (SCRI), we are committed to staying at the forefront of advanced treatments to provide our patients with the best possible care. We are excited to introduce EYLEA® HD (aflibercept), the FDA-approved high-dose version of EYLEA®, as a groundbreaking solution for the treatment of advanced neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), and diabetic retinopathy. The original EYLEA® was approved by the FDA in 2011 as an anti-vascular endothelial growth factor agent designed to block the growth of new blood vessels and inhibit fluid from passing through blood vessels in the eye.

Understanding AMD

AMD is a progressive deterioration of sight, with dry and wet classifications. Wet AMD involves abnormal blood vessel growth beneath the retina, leading to leakage, swelling, and damage to the macula – the central part of the retina responsible for sharp vision. This can result in vision loss, distortion, and blind spots in the central visual field.

Importance of Early Treatment

Early stages of wet AMD may not exhibit noticeable symptoms, but as the disease progresses, rapid and severe vision loss can occur. If left untreated, permanent vision loss and blindness may ensue. Treatment options often involve anti-VEGF drugs, which block abnormal blood vessels and reduce fluid and blood leakage in the retina.

EYLEA® HD stands out as a high-dose version of the well-established EYLEA medication. Administered through injections, it targets the underlying causes of wet AMD, offering a remarkable impact on prognosis. By blocking vascular endothelial growth factor (VEGF), EYLEA® HD helps prevent abnormal blood vessel growth and reduce fluid leakage, ultimately preserving and providing some improvement towards vision.

Diabetic Retinopathy and Diabetic Macular Edema

Diabetic retinopathy, a complication of diabetes, damages the blood vessels in the retina, leading to vision problems. Diabetic macular edema (DME) occurs when fluid accumulates in the macula, causing vision loss and distortion. Treatment options for these conditions include laser therapy and intravitreal injections of medications, such as anti-VEGF drugs or steroids. Controlling blood sugar levels and managing blood pressure are crucial in reducing the risk of developing DME. Early detection and treatment are paramount, as proper eyecare can prevent or delay further vision loss and improve overall visual function in people with diabetic retinopathy.

Expert Care at SCRI

The Retina Specialists at South Carolina Retina Institute are dedicated professionals with extensive experience in the diagnosis and treatment of eye conditions. At SCRI, we understand that each patient is unique and deserving of a specialized treatment approach. Dr. Nicolas Marchese and Dr. Jorge Jiménez, our skilled Vitreoretinal Surgeons, are board-certified in treating diseases and performing surgery on the vitreous and retina. Our medical offices in Conway and Murrells Inlet are dedicated to helping individuals throughout Myrtle Beach and the Grand Strand preserve their eyesight.

EYLEA® HD represents a significant advancement in the treatment of ophthalmic conditions, offering new hope for patients dealing with wet AMD, diabetic retinopathy, and DME. At South Carolina Retina Institute, we are proud to provide our patients with access to this innovative therapy, ensuring the highest standard of care for their visual health. Contact us today to schedule a consultation and learn more about how we can help to make a difference in your eye health journey.